Uriviga 0.2 Tablet contains Tamsulosin 0.2mg, a selective alpha-1 adrenergic receptor blocker used for the management of benign prostatic hyperplasia (BPH). It helps in relieving lower urinary tract symptoms such as difficulty in urination, weak stream, and frequent urination.
Tamsulosin works by relaxing smooth muscles in the prostate and bladder neck, improving urine flow and reducing urinary retention. This targeted mechanism ensures symptomatic relief and better quality of life for patients with BPH.
This tablet is commonly prescribed for chronic management of BPH and is particularly useful in older male patients who require long-term therapy. Its oral dosage ensures convenient administration and better patient compliance.
For PCD pharma franchise partners, Uriviga 0.2 Tablet is a high-demand urology product, available at the best price for PCD pharma franchise. Its proven clinical efficacy, consistent prescription trends, and strong patient demand make it a valuable addition to any urology or prostate care product portfolio.
Common side effects may include dizziness, headache, mild fatigue, and nasal congestion. Rare but serious side effects include severe hypotension, fainting, or allergic reactions. Patients should report severe or persistent symptoms to their doctor.
Uriviga 0.2 Tablet is indicated for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia, including difficulty in urination, weak urine stream, and urinary frequency.
Uriviga 0.2 Tablet should be taken exactly as prescribed, usually 30 minutes after the same meal each day. Caution is advised in patients with low blood pressure, liver disease, or a history of heart problems. Avoid sudden position changes to prevent dizziness or fainting.
Store Uriviga 0.2 Tablet in a cool, dry place away from direct sunlight and moisture. Keep out of reach of children and do not use after the expiry date printed on the packaging.